New England Peptide Expands Custom Antibody Program - Company Conjugates Polyclonal Antibodies to Gold, Biotin


Gardner, Mass., September 10, 2007 – In an effort to actively expand its custom offerings, New England Peptide, LLC (NEP) is now conjugating polyclonal antibodies to gold and biotin.

“The new conjugation possibilities add to long list of host species and polyclonal protocols that NEP offers,” says Dave Robinson, CEO, “and further NEP’s goal of providing a full suite of polyclonal antibody services.”

“We are committed to meeting customer needs as comprehensively as possibly, while maintaining the quality and service for which NEP has become known,” states Robinson. “Growing the custom antibody program is one key way we can serve our market better.”

According to Robinson, NEP has gained a reputation throughout the peptide industry for quality peptides and exceptional customer service – two ingredients necessary for successful custom polyclonal antibodies. The company provides:

• An ELISA success rate of greater than 99 percent;
• Average ELISA titer of 1:1,100,000;
• 100 percent guaranteed customer satisfaction.

New England Peptide (www.newenglandpeptide.com) designs and manufactures peptide and antibody products for drug discovery organizations worldwide. Headquartered in Gardner, Mass., and founded in 1998, the company specializes in custom peptide synthesis and polyclonal antibody production.

#

 

http://www.prweb.com/releases/2007/09/prweb552118.htm 

Testimonials

"Over the past 8 years we have used NEP for synthesis of many hundreds of peptides. The quality of NEP’s product is consistently very high. The company is deeply knowledgeable in all aspects of peptide synthesis, highly collaborative, and keenly interested in meeting the changing needs of their customers with respect to scale and formatting for delivery of peptides. One example is their flash-purified product which meets the need for initial draft-level evaluation without breaking the bank. Our experience with NEP’s antibody production capabilities has also been very good..."
Steven Carr, PhD - Director of Proteomics, Broad Institute